1887

Abstract

Purpose. To analyse the species distribution and the susceptibility profiles to the major antifungal agents of Candida isolated from bloodstream infections (BSIs) in both intensive care units (ICUs) and non-ICU wards in a tertiary care hospital in Italy from 2010 until 2015.

Methodology. Episodes of Candida BSI were recorded in a retrospective observational cohort study. Yeasts were isolated from both blood and intravascuIar devices (IVDs) and their susceptibility to antifungal drugs was tested using the microdilution method.

Results. 514 Candida BSIs were evidenced and 19 % of these episodes were associated with the presence of an IVD. The trend of the general incidence increased significantly throughout the study period, ranging from 1.42 to 3.63 (mean 2.52) episodes/1000 admissions. The incidence of Candida BSIs and IVD-associated candidaemia was significantly higher in ICUs relative to the other wards. The most frequently isolated species were C. albicans and C. parapsilosis complex, with the latter presenting a significant increased trend of isolation. C. parapsilosis complex was most frequently involved in IVD-related candidaemia, coinfections and late recurrent infections. Furthermore, the MIC50s of C. parapsilosis complex were significantly enhanced for echinocandins compared to the MIC50s for the same drugs and the other yeasts, while the MIC50s of C. albicans for amphotericin B showed a significant increase during the study period, ranging from 0.1 to 0.5 µg ml.

Conclusions. A progressively enhanced incidence of Candida BSIs, a relatively high impact of C. parapsilosis complex and changes in the susceptibility profiles of the isolated yeasts were evidenced during the observation period.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000505
2017-07-08
2019-10-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/7/990.html?itemId=/content/journal/jmm/10.1099/jmm.0.000505&mimeType=html&fmt=ahah

References

  1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133–163 [CrossRef][PubMed]
    [Google Scholar]
  2. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis 2012;73:45–48 [CrossRef][PubMed]
    [Google Scholar]
  3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309–317 [CrossRef][PubMed]
    [Google Scholar]
  4. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L et al. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006;27:359–366 [CrossRef][PubMed]
    [Google Scholar]
  5. Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 2013;51:4167–4172 [CrossRef][PubMed]
    [Google Scholar]
  6. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015;41:285–295 [CrossRef][PubMed]
    [Google Scholar]
  7. Barchiesi F, Orsetti E, Osimani P, Catassi C, Santelli F et al. Factors related to outcome of bloodstream infections due to Candida parapsilosis complex. BMC Infect Dis 2016;16:387 [CrossRef][PubMed]
    [Google Scholar]
  8. Türel O. Newer antifungal agents. Expert Rev Anti Infect Ther 2011;9:325–338 [CrossRef][PubMed]
    [Google Scholar]
  9. Fera MT, La Camera E, de Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 2009;7:981–998 [CrossRef][PubMed]
    [Google Scholar]
  10. Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Methods Mol Biol 2016;1508:17–65[CrossRef]
    [Google Scholar]
  11. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. Antimicrob Agents Chemother 2011;55:561–566 [CrossRef][PubMed]
    [Google Scholar]
  12. Asmundsdóttir LR, Erlendsdóttir H, Gísladóttir AL, Gottfredsson M. Molecular epidemiology of late recurrent candidaemia—a population-based study in Iceland. Clin Microbiol Infect 2012;18:195–201 [CrossRef][PubMed]
    [Google Scholar]
  13. Cleri DJ, Corrado ML, Seligman SJ. Quantitative culture of intravenous catheters and other intravascular inserts. J Infect Dis 1980;141:781–786 [CrossRef][PubMed]
    [Google Scholar]
  14. Ghosh AK, Paul S, Sood P, Rudramurthy SM, Rajbanshi A et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the rapid identification of yeasts causing bloodstream infections. Clin Microbiol Infect 2015;21:372–378 [CrossRef][PubMed]
    [Google Scholar]
  15. Pinto A, Halliday C, Zahra M, van Hal S, Olma T et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS One 2011;6:e25712 [CrossRef][PubMed]
    [Google Scholar]
  16. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012;50:2846–2856 [CrossRef][PubMed]
    [Google Scholar]
  17. Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43:1829–1835 [CrossRef][PubMed]
    [Google Scholar]
  18. Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection 2013;41:655–662 [CrossRef][PubMed]
    [Google Scholar]
  19. Bassetti M, Merelli M, Ansaldi F, de Florentiis D, Sartor A et al. Clinical and therapeutic aspects of candidemia: a five year single centre study. PLoS One 2015;10:e0127534 [CrossRef][PubMed]
    [Google Scholar]
  20. Colombo AL, Nucci M, Salomão R, Branchini ML, Richtmann R et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999;34:281–286 [CrossRef][PubMed]
    [Google Scholar]
  21. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 2004;38:311–320 [CrossRef][PubMed]
    [Google Scholar]
  22. Tedeschi S, Tumietto F, Giannella M, Bartoletti M, Cristini F et al. Epidemiology and outcome of candidemia in internal medicine wards: a regional study in Italy. Eur J Intern Med 2016;34:39–44 [CrossRef][PubMed]
    [Google Scholar]
  23. Eliakim-Raz N, Babaoff R, Yahav D, Yanai S, Shaked H et al. Epidemiology, microbiology, clinical characteristics, and outcomes of candidemia in internal medicine wards-a retrospective study. Int J Infect Dis 2016;52:49–54 [CrossRef][PubMed]
    [Google Scholar]
  24. Bruder-Nascimento A, Camargo CH, Sugizaki MF, Sadatsune T, Montelli AC et al. Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital. BMC Res Notes 2010;3:1 [CrossRef][PubMed]
    [Google Scholar]
  25. Delfino D, Scordino F, Pernice I, Lo Passo C, Galbo R et al. Potential association of specific Candida parapsilosis genotypes, bloodstream infections and colonization of health workers' hands. Clin Microbiol Infect 2014;20:O946–O951 [CrossRef][PubMed]
    [Google Scholar]
  26. Branchini ML, Pfaller MA, Rhine-Chalberg J, Frempong T, Isenberg HD. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol 1994;32:452–456[PubMed]
    [Google Scholar]
  27. Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002;40:1244–1248 [CrossRef][PubMed]
    [Google Scholar]
  28. Brunetti G, Visconti V, Ghezzi MC, Giordano A, Raponi G. The correlation between biofilm production and catheter related blood stream infections sustained by Candida. A case control study. Adv Exp Med Biol 2017; in press
    [Google Scholar]
  29. Levin AS, Costa SF, Mussi NS, Basso M, Sinto SI et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998;30:243–249 [CrossRef][PubMed]
    [Google Scholar]
  30. Posteraro B, Spanu T, Fiori B, de Maio F, de Carolis E et al. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. Antimicrob Agents Chemother 2015;59:3944–3955 [CrossRef][PubMed]
    [Google Scholar]
  31. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012;50:1199–1203 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000505
Loading
/content/journal/jmm/10.1099/jmm.0.000505
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error